Cardiovascular

Educational resources

Measuring blood sugar on finger_AS

Best practice treatment and management of patients with type 2 diabetes, cardiovascular disease, and heart failure

By Development Group—Javaid (Chair) Anand Assomull Holmes Karalliedde

This management algorithm was developed by a multidisciplinary expert panel: Javaid et al with the support of an educational grant from AstraZeneca. Information intended for UK healthcare professionals.

22-BM-330474 Index image

Anticoagulation management for elderly patients with NVAF, CKD and other comorbidities

Developed and funded by the Bristol Myers Squibb/Pfizer Alliance

This promotional webinar was organised and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals only.
Click HERE to view ELIQUIS (apixaban) prescribing information and adverse events reporting

Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com  or 0800 731 1736 (UK).

432-GB-2200204  May 2022

Index image

Identify, optimise treatment, refer—treating familial hypercholesterolaemia (FH) in primary care

Commissioned by Amgen Ltd

This eLearning module has been commissioned and funded by Amgen Ltd and developed in partnership with Guidelines.
By logging in to this page you confirm your understanding that you are about to view content intended for UK HCPs only. 
The content has been developed in collaboration with, and funded by, Amgen Ltd.
SC-UKIE-AMG145-00785 | December 2021

Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes

Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes—a patient case study

Commissioned by Bayer plc

This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto(rivaroxaban)   
PP-XAR-GB-2416 March 2022

Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants

Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants—a patient case study

Commissioned by Bayer plc

This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto(rivaroxaban)   
PP-XAR-GB-2415 January 2022